Both in Pharmaceuticals
Aktis Oncology vs Arbutus Biopharma
Over the past year AKTS returned −34.8% and ABUS returned −15.0%; their daily moves had a correlation of 0.28.
AKTS −34.8% ABUS −15.0%Growth of $1, one year, split-adjusted
| Metric | AKTS | ABUS |
|---|---|---|
| Price | $14.61 | $3.93 |
| Market cap | $812.3M | $777.6M |
| Today | +0.10% | −1.88% |
| 1 month | −21.1% | −16.0% |
| 6 months | −24.9% | −10.8% |
| Year to date | — | −18.4% |
| 1 year | — | −17.0% |
| Revenue growth (YoY) | — | −90.6% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −713.5% | −512.0% |
| P/E (TTM) | — | 5.1× |
| Price / sales | — | 4.3× |
| Net cash | $517.3M | $89.5M |
| Dividend yield | — | — |
| Volatility (60d) | 55.1% | 36.9% |
| Short % of float | 18.3% | 15.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).